We are live on ! Find out more
&Partners

&Partners Portfolio holdings

AUM $27.3B Turnover 11.7%
1-Year Est. Return 21.13%
 

&Partners is a wealth management firm built as a partnership in which its financial advisors are also its owners. Its founding partner and chief executive, David Kowach, headed Wells Fargo Advisors until 2019. The firm was formerly named Wiley Bros.-Aintree Capital, a Nashville brokerage and advisory firm that has been open since 1945 and was acquired by David Kowach's group in 2023.

This Fund
S&P 500
This Quarter Est. Return
+1.92%
1 Year Est. Return
+21.13%
3 Year Est. Return
+86.86%
5 Year Est. Return
+85.69%
10 Year Est. Return
–
AUM
$27.3B
AUM Growth
+$2.89B
Cap. Flow
+$2.72B
Cap. Flow %
9.98%
Top 10 Hldgs %
22.6%
Holding
2,743
New
234
Increased
1,706
Reduced
672
Closed
87
Avg Time Held
1.7 years
Top 10 Avg Time Held
2.8 years
Top 20 Avg Time Held
2.6 years

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$83.9M
2
NVDA icon
NVIDIA
NVDA
+$69.9M
3
AAPL icon
Apple
AAPL
+$67.4M
4
IVV icon
iShares Core S&P 500 ETF
IVV
+$46.6M
5
MU icon
Micron Technology
MU
+$44.8M

Sector Composition

Rank Sector Weight
1 Miscellaneous 45.91%
2 Technology 19.78%
3 Financials 7.28%
4 Healthcare 5.35%
5 Industrials 5.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PTLO icon
2601
Portillo's
PTLO
$472M
$67K ﹤0.01%
18,987
+140
+0.7% +$620
2025 Q3
4 quarters
SABR icon
2602
Sabre
SABR
$690M
$63.4K ﹤0.01%
29,902
-2,045
-6% -$4.19K
2024 Q4
7 quarters
ASG icon
2603
Liberty All-Star Growth Fund
ASG
$294M
$54.6K ﹤0.01%
+11,030
New +$57.5K
2026 Q3
0 quarters
OFS icon
2604
OFS Capital
OFS
$47M
$48.9K ﹤0.01%
13,500
– –
2020 Q4
23 quarters
BBAI icon
2605
BigBear.ai
BBAI
$842M
$45.6K ﹤0.01%
17,203
+1,203
+8% +$3.62K
2025 Q2
5 quarters
RXRX icon
2606
Recursion Pharmaceuticals
RXRX
$1.76B
$43.8K ﹤0.01%
+10,616
New +$36K
2026 Q3
0 quarters
CRBU icon
2607
Caribou Biosciences
CRBU
$35.2M
$41.3K ﹤0.01%
32,505
– –
2025 Q2
5 quarters
EOSEW icon
2608
Eos Energy Enterprises Warrant
EOSEW
$9.9M
$38.9K ﹤0.01%
+14,213
New +$46.9K
2026 Q3
0 quarters
TBLA icon
2609
Taboola.com
TBLA
$538M
$34.3K ﹤0.01%
+10,196
New +$44K
2026 Q3
0 quarters
EDIT icon
2610
Editas Medicine
EDIT
$273M
$32.8K ﹤0.01%
+12,773
New +$37.4K
2026 Q3
0 quarters
CABA icon
2611
Cabaletta Bio
CABA
$227M
$31.2K ﹤0.01%
16,245
+45
+0.3% +$127
2026 Q2
1 quarter
LAC icon
2612
Lithium Americas
LAC
$517M
$29.7K ﹤0.01%
10,916
+729
+7% +$2.24K
2026 Q2
1 quarter
VVR icon
2613
Invesco Senior Income Trust
VVR
$429M
$29K ﹤0.01%
10,031
-42
-0.4% -$124
2024 Q2
9 quarters
OPEN icon
2614
Opendoor
OPEN
$1.18B
$27.7K ﹤0.01%
+11,596
New +$41.6K
2026 Q3
0 quarters
WIT icon
2615
Wipro
WIT
$20B
$27.2K ﹤0.01%
16,475
-4,820
-23% -$8.85K
2026 Q1
2 quarters
ALLO icon
2616
Allogene Therapeutics
ALLO
$241M
$24.9K ﹤0.01%
15,575
+575
+4% +$1.09K
2026 Q1
2 quarters
AOA icon
2617
iShares Core 80/20 Aggressive Allocation ETF
AOA
$3.25B
$23.9K ﹤0.01%
+10,246
New +$1M
2026 Q3
0 quarters
ELTX icon
2618
Elicio Therapeutics
ELTX
$45M
$18.2K ﹤0.01%
10,000
– –
2025 Q2
5 quarters
FSP icon
2619
Franklin Street Properties
FSP
$40.2M
$9.42K ﹤0.01%
25,000
– –
2025 Q2
5 quarters
HRTX icon
2620
Heron Therapeutics
HRTX
$51.9M
$7.19K ﹤0.01%
22,927
-705
-3% -$267
2026 Q1
2 quarters
ASGI.RT icon
2621
DELISTED
abrdn Global Infrastructure Income Fund Rights
ASGI.RT
$1.26K ﹤0.01%
+101,246
New +$1.27K
2026 Q3
0 quarters
NMCO.RT icon
2622
DELISTED
Nuveen Municipal Credit Opportunities Fund Rights
NMCO.RT
$264 ﹤0.01%
+10,548
New +$210
2026 Q3
0 quarters
AAOI icon
2623
Applied Optoelectronics
AAOI
$3.7B
– –
-1,592
Closed -$240K –
AHCO icon
2624
AdaptHealth
AHCO
$1.01B
– –
-39,665
Closed -$413K –
APO.PRA icon
2625
DELISTED
Apollo Global Management Series A
APO.PRA
– –
-3,747
Closed -$228K –

Similar funds

&Partners's Q3 2026 Portfolio in Review

As of Q3 2026, &Partners held 2,743 positions worth $27.3B, up 12% from $24.4B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

&Partners deployed $2.72B of net new capital in Q3 2026, opening 234 new positions and adding to 1,706 existing holdings. Its largest new stake was First Trust Nasdaq Pharmaceuticals ETF: 340,063 shares worth $14.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 46% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Salesforce, an estimated $35.2M trimmed.

  • &Partners's largest Q3 2026 buy was First Trust Nasdaq Pharmaceuticals ETF: 340,063 shares worth $14.1M.
  • &Partners added most to Microsoft in Q3 2026, an estimated $83.9M increase.
  • &Partners's biggest Q3 2026 reduction was Salesforce, cutting an estimated $35.2M.
  • &Partners fully exited First Trust Nasdaq Semiconductor ETF in Q3 2026, selling an estimated $16.9M.
  • &Partners's ten largest holdings make up 23% of its $27.3B portfolio in Q3 2026.
  • &Partners opened 234 new positions and closed 87 in Q3 2026.
  • &Partners's portfolio value rose 12% quarter-over-quarter to $27.3B.

Based on &Partners's 13F filing for Q3 2026, filed 16 Nov 2026.